Can a simple blood thinner keep brain tumor patients safe from clots?
NCT ID NCT05683808
First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This study is testing whether the blood thinner apixaban can safely prevent blood clots in people newly diagnosed with a fast-growing brain tumor called grade 4 glioma. About 40 adults will take apixaban while receiving standard radiation and chemotherapy. The main goal is to see if the drug causes serious bleeding, and the secondary goal is to check if it actually prevents clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apixaban (a blood thinner)
What this could lead to
If it works, this could point toward a safe way to prevent blood clots in brain tumor patients, reducing hospitalizations and complications.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The main risk is bleeding, including in the brain, which could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.